Cargando…

Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents

The impact of direct-acting antivirals (DAAs) for hepatitis C virus (HCV) on burden of cirrhotic and noncirrhotic hepatocellular carcinoma (HCC) has not been examined. We assessed recent trends in liver disease etiologies of HCC and proportion of noncirrhotic HCC since DAAs introduction. METHODS: Cl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mathur, Karan, Mazhar, Areej, Patel, Milin, Dakhoul, Lara, Burney, Heather, Liu, Hao, Nephew, Lauren, Chalasani, Naga, deLemos, Andrew, Gawrieh, Samer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568358/ https://www.ncbi.nlm.nih.gov/pubmed/34730559 http://dx.doi.org/10.14309/ctg.0000000000000420

Ejemplares similares

Distinctive Features and Outcomes of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Disease: A US Multicenter Study
por: deLemos, Andrew, et al.
Publicado: (2020)

Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma Are Not Explained by Differences in Comorbidities, Liver Disease Severity, or Tumor Burden
por: Dakhoul, Lara, et al.
Publicado: (2018)

Hepatocellular Carcinoma in Hispanic Patients: Trends and Outcomes in a Large United States Cohort
por: Pomenti, Sydney, et al.
Publicado: (2020)

Hepatocellular Carcinomas in Cirrhotic and Noncirrhotic Human Livers Share Angiogenic Characteristics
por: Zeng, Wenjiao, et al.
Publicado: (2010)

Prognostic and diagnostic value of SOX9 in cirrhotic and noncirrhotic hepatocellular carcinoma
por: Xu, Zhong-Ping, et al.
Publicado: (2021)

Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC
por: Sydor, Svenja, et al.
Publicado: (2020)

Hepatocellular Carcinoma in Cirrhotic Versus Noncirrhotic Livers: Clinicomorphologic Findings and Prognostic Factors
por: Karaoğullarından, Ümit, et al.
Publicado: (2023)

Risk factors for hepatocellular carcinoma in cirrhosis due to nonalcoholic fatty liver disease: A multicenter, case-control study
por: Corey, Kathleen E, et al.
Publicado: (2017)

Integrative omics analysis identifies macrophage migration inhibitory factor signaling pathways underlying human hepatic fibrogenesis and fibrosis
por: Liu, Zhipeng, et al.
Publicado: (2019)

Comorbidity Burden May Be Associated with Increased Mortality in Patients with Severe Acute Liver Injury Referred for Liver Transplantation
por: Steiner-Temnykh, Lindsey, et al.
Publicado: (2020)

Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era
por: Mathur, Poonam, et al.
Publicado: (2018)

3550 Understanding Racial Disparities in Hepatocellular Carcinoma Treatments and Outcomes
por: Nephew, Lauren Devore, et al.
Publicado: (2019)

A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus
por: Fawsitt, Christopher G., et al.
Publicado: (2019)

Dynamic Alterations to Hepatic MicroRNA-29a in Response to Long-Term High-Fat Diet and EtOH Feeding
por: Liang, Tiebing, et al.
Publicado: (2023)

Idiopathic Noncirrhotic Portal Hypertension: An Appraisal
por: Lee, Hwajeong, et al.
Publicado: (2016)

HIV/HCV Antiviral Drug Interactions in the Era of Direct-acting Antivirals
por: Rice, Donald P., et al.
Publicado: (2016)

Automated assessment of steatosis in murine fatty liver
por: Sethunath, Deepak, et al.
Publicado: (2018)

Idiopathic noncirrhotic portal hypertension: current perspectives
por: Riggio, Oliviero, et al.
Publicado: (2016)

Fibrolamellar Hepatocellular Carcinoma and Noncirrhotic Hyperammonemic Encephalopathy
por: Suarez, Oscar, et al.
Publicado: (2018)

Extra-hepatic comorbidity burden significantly increases 90-day mortality in patients with cirrhosis and high model for endstage liver disease
por: Coppel, Scott, et al.
Publicado: (2020)

Severe Alcohol‐Associated Hepatitis Is Associated With Worse Survival in Critically Ill Patients With Acute on Chronic Liver Failure
por: Patidar, Kavish R., et al.
Publicado: (2021)

De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents
por: Kuftinec, Gabriela, et al.
Publicado: (2018)

Progressive Cholestasis and Biliary Cirrhosis After Initiating Oral Semaglutide: Report From the Drug-Induced Liver Injury Network
por: Ma, Jiayi, et al.
Publicado: (2022)

Antiviral therapy of HCV in the cirrhotic and transplant candidate
por: Herrine, Steven K., et al.
Publicado: (2006)

Antiviral Therapy in HCV-infected Decompensated Cirrhotics
por: Danish, Fazal A., et al.
Publicado: (2010)

Correlation of MicroRNA-16, MicroRNA-21 and MicroRNA-101 Expression with Cyclooxygenase-2 Expression and Angiogenic Factors in Cirrhotic and Noncirrhotic Human Hepatocellular Carcinoma
por: Zeng, Wenjiao, et al.
Publicado: (2014)

HCV-Associated Nephropathies in the Era of Direct Acting Antiviral Agents
por: Angeletti, Andrea, et al.
Publicado: (2019)

The ‘Viennese epidemic’ of acute HCV in the era of direct‐acting antivirals
por: Chromy, David, et al.
Publicado: (2022)

Significant Medical Comorbidities Are Associated With Lower Causality Scores in Patients Presenting With Suspected Drug-Induced Liver Injury
por: Ghabril, Marwan, et al.
Publicado: (2020)

Splenic Marginal Zone Lymphoma in the Setting of Noncirrhotic Portal Hypertension
por: Ratnayake, Saman, et al.
Publicado: (2015)

Challenging liver lesions in noncirrhotic patients: Report of three cases
por: Franceschini, Tania, et al.
Publicado: (2019)

Persistent Encephalopathy in a Noncirrhotic Patient: Do not Shun This Shunt
por: Kassamali, Farah, et al.
Publicado: (2020)

A new model to predict response to direct-acting antiviral therapy in decompensated cirrhotics due to hepatitis C virus
por: Debnath, Prasanta, et al.
Publicado: (2020)

GDF8 Contributes to Liver Fibrogenesis and Concomitant Skeletal Muscle Wasting
por: Culver, Alexander, et al.
Publicado: (2023)

Management of hepatitis C genotype 4 in the directly acting antivirals era
por: Hathorn, Emma, et al.
Publicado: (2016)

Hepatitis C virus infection in children in the era of direct-acting antiviral
por: Pawlowska, Malgorzata, et al.
Publicado: (2018)

Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
por: Stevenson, Heather L., et al.
Publicado: (2016)

Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation
por: Martin, Natasha K., et al.
Publicado: (2016)

Secular trends in cryoglobulinemia mortality in the USA in the era of direct-acting antivirals
por: Guo, Qianyu, et al.
Publicado: (2022)

Use of caudal pancreatectomy as a novel adjunct procedure to proximal splenorenal shunt in patients with noncirrhotic portal hypertension: A retrospective cohort study
por: Gupta, Shahana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_463p3kf0hf7gk3djef5o5fsqbr